{
    "nct_id": "NCT04039607",
    "official_title": "A Randomized, Multi-center, Phase 3 Study of Nivolumab in Combination With Ipilimumab Compared to Sorafenib or Lenvatinib as First-Line Treatment in Participants With Advanced Hepatocellular Carcinoma",
    "inclusion_criteria": "* Participants must have a diagnosis of HCC based on histological confirmation\n* Participants must have an advanced HCC\n* Participants must have at least one Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 measurable previously untreated lesion\n* Child-Pugh score 5 or 6\n* Eastern Cooperative Oncology Group (ECOG) performance status(PS) 0 or 1\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Known fibrolamellar HCC, sarcomatoid HCC, or mixed cholangiocarcinoma and HCC\n* Prior liver transplant\n* Episodes of hepatic encephalopathy (greater than or equal to [>=] Grade 2) within 12 months prior to randomization\n* Active brain metastases or leptomeningeal metastases\n\nOther protocol-defined inclusion/exclusion criteria apply.",
    "miscellaneous_criteria": ""
}